Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries
Authors:
Open Access
- 1 January 2007
- journal article
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 37 (7) , 304-311
Abstract
Kim SM, et al. Korean Circ J. 2007 Jul;37(7):304-311. http://dx.doi.org/10.4070/kcj.2007.37.7.304Keywords
This publication has 25 references indexed in Scilit:
- Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantationJACC, 2004
- Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary StenosesCirculation, 2004
- Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting StentsCirculation, 2004
- Economic impact of drug-eluting stents on hospital systems: a disease-state modelAmerican Heart Journal, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?JACC, 1996
- Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplastyJACC, 1996
- Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in CultureJournal of Cardiovascular Pharmacology, 1992
- Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-(3-(1-Cyclohexyl-5-tetrazolyl)propoxy)-1,2-dihydro-2-oxoquinoline and related compounds.Chemical and Pharmaceutical Bulletin, 1983